Paul K. Stockman
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 8
-
- Lung Cancer Treatments and Mutations 7
- Cell Biology top 5%
- Microtubule and mitosis dynamics 5
- Molecular Biology top 10%
- Genomics, phytochemicals, and oxidative stress 5
- Glutathione Transferases and Polymorphisms 5
- Fibroblast Growth Factor Research 5
- Hematology top 10%
- Acute Myeloid Leukemia Research 7
- Multiple Myeloma Research and Treatments 4
- Co-authors
- John D. HayesGeoffrey J. BeckettMalcolm RansonNaiyer A. RizviRonald B. NataleRamaswamy GovindanDariusz M. KowalskiSarah J. Kennedy
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Paul K. Stockman
39 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Oncology 935
- Pulmonary and Respiratory Medicine 737
- Cell Biology 323
- Molecular Biology 807
- Hematology 126
Countries citing papers authored by Paul K. Stockman
This map shows the geographic impact of Paul K. Stockman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul K. Stockman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul K. Stockman more than expected).
Fields of papers citing papers by Paul K. Stockman
This network shows the impact of papers produced by Paul K. Stockman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul K. Stockman. The network helps show where Paul K. Stockman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Paul K. Stockman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 118 | |
| 2 | 2019 | 16 | |
| 3 | 2017 | 3 | |
| 4 | Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trialbreakdown → | 2017 | 304 |
| 5 | 2017 | 8 | |
| 6 | 2017 | 149 | |
| 7 | 2013 | 46 | |
| 8 | 2013 | 34 | |
| 9 | 2012 | 61 | |
| 10 | 2012 | 1 | |
| 11 | 2012 | 53 | |
| 12 | 2010 | 85 | |
| 13 | 2009 | 194 | |
| 14 | 1996 | 17 | |
| 15 | 1992 | 9 | |
| 16 | 1989 | 3 | |
| 17 | 1989 | 3 | |
| 18 | 1987 | 25 | |
| 19 | 1986 | 53 | |
| 20 | 1985 | 80 |
About Paul K. Stockman
Paul K. Stockman is a scholar working on Hematology, Oncology, Pulmonary and Respiratory Medicine, Physiology and Gastroenterology, having authored 39 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Acute Myeloid Leukemia Research (7 papers), Lung Cancer Treatments and Mutations (7 papers), Genomics, phytochemicals, and oxidative stress (5 papers), Glutathione Transferases and Polymorphisms (5 papers), Fibroblast Growth Factor Research (5 papers), Microtubule and mitosis dynamics (5 papers) and Multiple Myeloma Research and Treatments (4 papers). The work is most often cited by research in Oncology (935 citations), Pulmonary and Respiratory Medicine (737 citations), Cell Biology (323 citations), Molecular Biology (807 citations) and Hematology (126 citations). Paul K. Stockman has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include John D. Hayes, Geoffrey J. Beckett, Malcolm Ranson, Naiyer A. Rizvi, Ronald B. Natale, Ramaswamy Govindan, Dariusz M. Kowalski, Sarah J. Kennedy, David Bodkin and Paul Germonpré. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Blood, Biochemical Journal and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.